Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 265

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 265
---
 securities, based on a price per share equal to 80% of the lowest price per attributed to such securities in the merger 
 and acquisition transaction.                                                                                                        |

In October 2021, the Company and 2020
CLA investors reached an agreement according to which, in connection with the raising of the 2021 Notes, the 2020 Notes will be converted
into Ordinary Shares upon the occurrence of an exit event (including an IPO or merger) of the Company based on a price per share equal
to 80% at a pre money valuation of $5,150.

On January 3, 2024, the Company extended
the due date of the 2020 Notes until April 30, 2024 and, subsequently, on April 26, 2024, further extended the due date until May 27,
2024.

| b. | In                                                                                              
 October 2024, the Company entered into an addendum to the 2020 CLAs (the “October 2024          
 CLA Addendum”) pursuant to which the Company will issue additional notes up to an additional    
 aggregate amount of $450 to certain lenders (the “Participating Lenders”). Pursuant             
 to the October 2024 CLA Addendum, the 2020 Notes held by the non-participating lenders will     
 bear interest at 8% per annum until maturity commencing as of July 1, 2024, and the 2020        
 Notes held by the Participating Lenders commencing on March 31, 2025. In addition, pursuant     
 to the October 2024 CLA Addendum, upon the earlier of March 31, 2025 or occurrence of an        
 IPO, the 2020 Notes principal and accrued interest will be automatically converted into 609,887 
 Ordinary Shares based on a pre money valuation of $5,150. In addition, upon conversion of       
 the CLAs to Ordinary Shares the Company will issue additional 553,640 Ordinary Shares to        
 the Participating Lenders which presents the additional amount provided by Participating        
 Lenders, the applicable accrued interest and the amount of $340 as a risk premium. As of        
 December 31, 2024, the Company received proceeds of $450 proceeds from the issuance of the      
 additional 2020 Notes. On March 31, 2025, the Company and the lenders signed an amendment       
 to the loan agreement to extend the maturity date until the earlier of August 31